Nektar Therapeutics (FRA:ITH0) Shiller PE Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ITH0 Nektar Therapeutics FRA:ITH0
51 GF Score
Price €60.14
GF Value €4.61
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nektar Therapeutics  (FRA:ITH0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Nektar Therapeutics Shiller PE Ratio Related Terms


Nektar Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Shiller PE Ratio Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nektar Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:ITH0 vs PHVS, PGEN, VERA: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Shiller PE Ratio falls into.


FRA:ITH0
51GF Score
Nektar Therapeutics FRA:ITH0
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Nektar Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Nektar Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.057/333.9520*333.9520
=-1.057

Current CPI (Jun. 2026) = 333.9520.

Nektar Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -4.238 241.428 -5.862
201612 -3.938 241.432 -5.447
201703 -5.849 243.801 -8.012
201706 -5.253 244.955 -7.162
201709 4.783 246.819 6.472
201712 -2.722 246.524 -3.687
201803 -7.267 249.554 -9.725
201806 67.093 251.989 88.916
201809 -7.180 252.439 -9.498
201812 -7.451 251.233 -9.904
201903 -9.090 254.202 -11.942
201906 -8.435 256.143 -10.997
201909 -7.583 256.759 -9.862
201912 -8.628 256.974 -11.213
202003 -10.655 258.115 -13.785
202006 -6.111 257.797 -7.916
202009 -7.786 260.280 -9.990
202012 -8.207 260.474 -10.522
202103 -8.443 264.877 -10.645
202106 -8.555 271.696 -10.515
202109 -8.964 274.310 -10.913
202112 -10.334 278.802 -12.378
202203 -6.503 287.504 -7.554
202206 -11.986 296.311 -13.508
202209 -4.686 296.808 -5.273
202212 -4.666 296.797 -5.250
202303 -10.142 301.836 -11.221
202306 -3.715 305.109 -4.066
202309 -3.319 307.789 -3.601
202312 -3.073 306.746 -3.345
202403 -2.612 312.332 -2.792
202406 -3.494 314.175 -3.714
202409 -2.418 315.301 -2.561
202412 0.478 315.605 0.506
202503 -3.438 319.799 -3.590
202506 -2.605 322.561 -2.697
202509 -1.604 324.800 -1.650
202512 -1.527 324.054 -1.574
202603 -1.552 330.213 -1.569
202606 -1.057 333.952 -1.057

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €60.14 is trading 1204.6% above its estimated GF Value™ of €4.61. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:ITH0:

  • Shiller PE Ratio:
  • GF Value™: €4.61 vs. price of €60.14 (1204.6% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
51GF Score

Get the complete analysis for FRA:ITH0

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.14
Price
€4.61
GF Value